These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27461515)

  • 21. Predicting escitalopram monotherapy response in depression: The role of anterior cingulate cortex.
    Tian S; Sun Y; Shao J; Zhang S; Mo Z; Liu X; Wang Q; Wang L; Zhao P; Chattun MR; Yao Z; Si T; Lu Q
    Hum Brain Mapp; 2020 Apr; 41(5):1249-1260. PubMed ID: 31758634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot study.
    Eyre HA; Eskin A; Nelson SF; St Cyr NM; Siddarth P; Baune BT; Lavretsky H
    Int J Geriatr Psychiatry; 2016 May; 31(5):510-7. PubMed ID: 26471432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence.
    Muhonen LH; Lahti J; Alho H; Lönnqvist J; Haukka J; Saarikoski ST
    Psychiatry Res; 2011 Mar; 186(1):53-7. PubMed ID: 20800901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
    Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder.
    Kasper S; Ebert B; Larsen K; Tonnoir B
    Int J Neuropsychopharmacol; 2012 Jul; 15(6):715-25. PubMed ID: 22008735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial.
    Bretlau LG; Lunde M; Lindberg L; Undén M; Dissing S; Bech P
    Pharmacopsychiatry; 2008 Mar; 41(2):41-7. PubMed ID: 18311683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
    Wade AG; Schlaepfer TE; Andersen HF; Kilts CD
    J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ATP-binding cassette sub-family F member 1 (ABCF1) is identified as a putative therapeutic target of escitalopram in the inflammatory cytokine pathway.
    Powell TR; Tansey KE; Breen G; Farmer AE; Craig IW; Uher R; McGuffin P; D'Souza UM; Schalkwyk LC
    J Psychopharmacol; 2013 Jul; 27(7):609-15. PubMed ID: 23719290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
    Bech P; Andersen HF; Wade A
    Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment.
    Lin KM; Chiu YF; Tsai IJ; Chen CH; Shen WW; Liu SC; Lu SC; Liu CY; Hsiao MC; Tang HS; Liu SI; Chang LH; Wu CS; Tsou HH; Tsai MH; Chen CY; Wang SM; Kuo HW; Hsu YT; Liu YL
    Pharmacogenet Genomics; 2011 Apr; 21(4):163-70. PubMed ID: 20859246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants.
    Ju C; Fiori LM; Belzeaux R; Theroux JF; Chen GG; Aouabed Z; Blier P; Farzan F; Frey BN; Giacobbe P; Lam RW; Leri F; MacQueen GM; Milev R; Müller DJ; Parikh SV; Rotzinger S; Soares CN; Uher R; Li Q; Foster JA; Kennedy SH; Turecki G
    Transl Psychiatry; 2019 Oct; 9(1):254. PubMed ID: 31594917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response.
    Fiori LM; Orri M; Aouabed Z; Théroux JF; Lin R; Nagy C; Frey BN; Lam RW; MacQueen GM; Milev R; Müller DJ; Parikh SV; Rotzinger S; Uher R; Foster JA; Kennedy SH; Turecki G
    Transl Psychiatry; 2021 Aug; 11(1):439. PubMed ID: 34420030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Debunking the placebo effect in depression: the effect of patient and investigator expectation on escitalopram efficacy.
    Nehama Y; Rabinowitz I; Baruch Y; Mandel A; Lurie I; Barak Y
    Int Clin Psychopharmacol; 2014 Mar; 29(2):106-10. PubMed ID: 24172161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential serum biomarkers for the prediction of the efficacy of escitalopram for treating depression.
    Xu Y; Wei H; Zhu Y; Zhu Y; Zhang N; Qin J; Zhu X; Yu M; Li Y
    J Affect Disord; 2019 May; 250():307-312. PubMed ID: 30875673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.
    Uher R; Perroud N; Ng MY; Hauser J; Henigsberg N; Maier W; Mors O; Placentino A; Rietschel M; Souery D; Zagar T; Czerski PM; Jerman B; Larsen ER; Schulze TG; Zobel A; Cohen-Woods S; Pirlo K; Butler AW; Muglia P; Barnes MR; Lathrop M; Farmer A; Breen G; Aitchison KJ; Craig I; Lewis CM; McGuffin P
    Am J Psychiatry; 2010 May; 167(5):555-64. PubMed ID: 20360315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study.
    Uher R; Mors O; Rietschel M; Rajewska-Rager A; Petrovic A; Zobel A; Henigsberg N; Mendlewicz J; Aitchison KJ; Farmer A; McGuffin P
    J Clin Psychiatry; 2011 Nov; 72(11):1478-84. PubMed ID: 22127194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Otte C; Hinkelmann K; Moritz S; Yassouridis A; Jahn H; Wiedemann K; Kellner M
    J Psychiatr Res; 2010 Apr; 44(6):339-46. PubMed ID: 19909979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Escitalopram versus placebo in the treatment of dysthymic disorder.
    Hellerstein DJ; Batchelder ST; Hyler S; Arnaout B; Toba C; Benga I; Gangure D
    Int Clin Psychopharmacol; 2010 May; 25(3):143-8. PubMed ID: 21811192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.